Leading roll of North American Interventional Cardiology and Peripheral Vascular Devices in Asia Market
The North American interventional cardiology and peripheral vascular devices market is consolidated with five key players that contributed to a collective share of 91% in 2013. The notable players of this market include Abbott Laboratories (U.S.), Cordis Corporation (U.S.), Medtronic, Inc. (U.S.), Boston Scientific Corporation (U.S.), and Covidien, Inc. (U.S.). In 2013, Boston Scientific Corporation held the maximum share of 31% in the North American interventional cardiology and peripheral devices market.
Technology adoption was found to be the major objective of different business approaches by leading players over the past few years. Notable players introduced novel technologies to minimize post-surgical complications either through product line extensions or acquisition of proprietary technology of tier III and tier IV players. The new product launch strategy commanded the largest share of 37% of the total strategiesadopted by leading players from 2011 to 2014. Notable product launches in the North American interventional cardiology and peripheral devices market include Abbott’s XIENCE Xpedition Everolimus Eluting Coronary Stent Systemand Covidien’s Viance crossing catheter and Enteer Re-entry System. Strategic acquisitions were also found to be a major trend in the market. In 2013, Abbott Laboratories acquired IDEV Technologies to leverage IDEV’s next-generation SUPERA Veritas stent system; whereas, in 2013, Covidien acquired CV Ingenuity to incorporate drug-coated balloon technology in its existing portfolio.
The peripheral intervention and DVT/PE treatment were identified as the major focus areas of the leading players over the last few years. In 2013, Cordis Corporation acquired Flexible Stenting Solutions, Inc. to leverage its innovative flexible peripheral arterial, venous, and biliary stents; while, in 2012, Abbott introduced Absolute Pro, a vascular self-expanding stent system, for treatment of the iliac artery disease. In 2012, Boston Scientific acquired BridgePoint Medical to integrate BridgePoint’s first-of-its-kind crossing and re-entry systems for the treatment of coronary chronic total occlusions (CTOs).The drug-eluting stent segment also gainedsignificant attention from leading players inthe North American interventional cardiology and peripheral devices market. In 2011, Abbott Laboratories introduced a XIENCE V (XIENCE nano)to minimize the risk of restenosis associated with small-vessel coronary angioplasty. The increasing volume of peripheral intervention and DVT/PE treatment procedures are expected to lure new entrants in the North American interventional cardiology and peripheral vascular devices market in the coming years.
Related Reports:
North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon (Plain/Old, Cutting), Stent (Bioabsorbable, Drug-Eluting), Catheter (IVUS, OCT), IVC Filter (Retrievable), Endovascular Stent Graft - Forecast to 2018
Contact:
Mr. Rohan
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: [email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
